阿那曲唑治疗复发性雌激素受体/孕激素受体阳性子宫内膜癌的2期研究:PARAGON试验——ANZGOG 0903
这项由研究者发起的单臂、开放标签2期试验评估阿那曲唑1 mg/d用于雌激素受体和/或孕激素受体阳性、未接受过激素治疗的转移性子宫内膜癌患者。82例可评估患者3个月临床获益率为44%(95%CI:34-55%),中位无进展生存期3.2个月(95%CI:2.8-5.4);3个月时获得临床获益的患者与疾病进展患者相比,多个生活质量领域有临床显著改善。
要点
- 阿那曲唑1 mg/d在82例可评估患者中3个月临床获益率为44%(95%CI:34-55%)。
- 依据RECIST标准的最佳疗效为部分缓解6例(7%;95%CI:3-15%),中位无进展生存期3.2个月(95%CI:2.8-5.4)。
- 3个月时获得临床获益的患者与疾病进展患者相比,情绪功能(39% vs 6%;p=0.002)、认知功能(45% vs 19%;p=0.021)、疲乏(47% vs 19%;p=0.015)和总体健康状况(42% vs 9%;p=0.003)有临床显著改善。
核心结论
- 尽管阿那曲唑的客观缓解率相对较低,但44%的雌激素受体/孕激素受体阳性转移性子宫内膜癌患者观察到临床获益,且与生活质量改善相关。
研究设计与样本
- 研究者发起的单臂、开放标签2期试验,阿那曲唑1 mg/d用于雌激素受体和/或孕激素受体阳性、未接受过激素治疗的转移性子宫内膜癌患者。
- 患者治疗至疾病进展或不可接受的毒性。
- 主要终点为3个月时的临床获益(缓解+疾病稳定);次要终点包括无进展生存期、生活质量和毒性。
主要发现
- 82例可评估患者3个月临床获益率为44%(95%CI:34-55%)。
- 依据RECIST标准的最佳疗效为部分缓解6例(7%;95%CI:3-15%)。
- 中位无进展生存期为3.2个月(95%CI:2.8-5.4);中位临床获益持续时间为5.6个月(95%CI:3.0-13.7)。
- 治疗耐受性良好。
- 3个月时获得临床获益的患者与疾病进展患者相比,多个生活质量领域有临床显著改善:情绪功能(39% vs 6%;p=0.002)、认知功能(45% vs 19%;p=0.021)、疲乏(47% vs 19%;p=0.015)和总体健康状况(42% vs 9%;p=0.003)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The clinical benefit rate with aromatase inhibitors and the impact of treatment on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 trial of anastrozole in endometrial cancer. METHODS: Investigator initiated single-arm, open label trial of anastrozole, 1 mg/d in patients with ER and/or PR positive hormonal therapy naive metastatic endometrial cancer. Patients were treated until progressive disease (PD) or unacceptable toxicity. The primary end-point was clinical benefit (response + stable disease) at 3 months. Secondary endpoints include progression-free survival (PFS), quality of life (QOL) and toxicity. RESULTS: Clinical benefit rate in 82 evaluable patients at 3 months was 44% (95% CI: 34-55%) with a best response by RECIST of partial response in 6 pts. (7%; 95% CI: 3-15%). The median PFS was 3.2 months (95% CI: 2.8-5.4). Median duration of clinical benefit was 5.6 months (95% CI: 3.0-13.7). Treatment was well tolerated. Patients who had clinical benefit at 3 months reported clinically significant improvements in several QOL domains compared to those with PD; this was evident by 2 months including improvements in: emotional functioning (39 vs 6%: p = 0.002), cognitive functioning (45 vs 19%: p = 0.021), fatigue (47 vs 19%: p = 0.015) and global health status (42 vs 9%: p = 0.003). CONCLUSION: Although the objective response rate to anastrozole was relatively low, clinical benefit was observed in 44% of patients with ER/PR positive metastatic endometrial cancer and associated with an improvement in QOL.
引用
- Mileshkin L, Edmondson R, O'Connell RL, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. Gynecol Oncol. 2019. PMID: 31130288. doi:10.1016/j.ygyno.2019.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。